Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
31.57+0.18 (+0.57%)
At close: 3:59 PM EDT
People also watch:
NVSSNYNSRGYAZNBAYRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open31.45
Prev Close31.39
Bid0.00 x
Ask0.00 x
Day's Range31.31 - 31.62
52wk Range29.89 - 35.13
1y Target EstN/A
Market Cap215.79B
P/E Ratio (ttm)23.47
Beta0.66
Volume387,613
Avg Vol (3m)904,979
Dividend & Yield1.02 (3.24%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire3 hours ago

    Harmony® Prenatal Test for assessment of Down syndrome and other chromosomal disorders receives CE mark

    OTCQX:RHHBY) today announced that the Harmony Prenatal Test for assessing the probability of Down syndrome (Trisomy 21) and other chromosomal disorders has received the CE mark. This enables laboratories to perform local in vitro diagnostic (IVD) testing in countries that accept the mandatory conformity marking.  Local testing availability permits laboratories to comply with reimbursement requirements and expedite test results for healthcare providers and expectant parents in their regions. "This is exceptionally good news as CE marking of the Harmony Prenatal Test will make highly accurate cfDNA testing accessible to a wider spectrum of pregnant women," said Professor Kypros Nicolaides, M.D., director of the Fetal Medicine Foundation and the Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in London.

  • PR Newswire5 hours ago

    FDA Grants Roche Label Extension for the cobas® EGFR Mutation Test v2 for use with Plasma as a Companion Diagnostic for TAGRISSO™

    PLEASANTON, Calif., Sept. 29, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX, RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension of the cobas ® EGFR ...

  • Morningstar23 hours ago

    Looking Abroad for Quality Bargains

    Six foreign stocks that are selling at compelling valuations.